May 8-10 saw - Europe's Leading Biopartnering and Investment Conference - Bio Trinity return to London. I was honoured to attend and speak at this fascinating event for those involved in the global bio tech industry. My panel focussed on -
The Opportunities for UK Life Sciences companies following Brexit
My fellow panellists comprised :
Shawn Manning, Managing Director, Akesios Associates, John Harris, CEO, OBN (UK), Leslie Galloway, Chairman, Ethical Medicines Industry Group (EMIG), Colin Hailey, Partner, Confluence Tax.
The discussion ranged widely across the Unitary Patent, to the Biomedical Catalyst, and future trade relations. The event polled the audience attitude to the UK's future post Brexit before and after the session and a remarkable change took place, with a shift in favour of optimism for the UK's future. I hope we prove them right!